Suppr超能文献

21-羟化酶缺乏症患儿长期治疗监测中,年生长速度标准差评分和生化参数测量的效用。

The utility of annual growth velocity standard deviation scores and measurements of biochemical parameters in long-term treatment monitoring of children with 21-hydroxylase deficiency.

机构信息

Department of Pediatrics, Division of Pediatric Endocrinology, Cukurova University Faculty of Medicine, Adana, Turkey.

出版信息

Hormones (Athens). 2022 Sep;21(3):391-397. doi: 10.1007/s42000-022-00354-1. Epub 2022 Mar 3.

Abstract

PURPOSE

This study aimed to investigate the utility of annual growth velocity (GV) standard deviation scores (SDSs) and compatibility and effectiveness of biochemical parameters in long-term treatment monitoring and management of 21-hydroxylase deficiency (21-OHD) in children.

METHODS

Fifty children with 21-OHD were included in this study, and the biochemical parameters obtained during 402 visits were retrospectively evaluated. The follow-up period was divided between two GV SDS groups (GV SDS < 2 and GV SDS ≥ 2) and compared with auxological, biochemical, and clinical findings.

RESULTS

Elevation of 17-hydroxyprogesterone (17-OHP) values was observed at 193/402 visits, and both adrenocorticotropic hormone (ACTH) and total testosterone (tT) were observed at 53 of 193 (27.5%) visits. The calculated cut-off value for 17-OHP was > 4.3 ng/ml, with a sensitivity of 85.48% and specificity of 37.59% in the GV SDS ≥ 2 group. In the GV SDS ≥ 2 group, the corrected final height SDS (cFH SDS) was lower, and the delta height was higher than in the GV SDS < 2 group (p = 0.005 and p = 0.008, respectively). Linear regression analysis of the GV SDSs revealed that 17-OHP values and the hydrocortisone dose (mg/m) were affected (β = 0.037, p = 0.035, and β =  - 0.147, p = 0.001, respectively).

CONCLUSIONS

Annual GV was critical in the final height (FH) of children with 21-OHD. However, we observed inconsistency between the biochemical parameters in the follow-ups, and there were difficulties in evaluating these markers. Therefore, annual GV SDSs and biochemical findings should be used together in patients with 21-OHD at follow-ups.

摘要

目的

本研究旨在探讨生长速度(GV)标准差评分(SDS)的应用价值,以及生物化学参数在长期治疗监测和 21-羟化酶缺乏症(21-OHD)患儿管理中的兼容性和有效性。

方法

本研究纳入了 50 例 21-OHD 患儿,回顾性评估了 402 次就诊时获得的生化参数。根据随访期的 GV SDS 是否大于等于 2 分为 GV SDS<2 组和 GV SDS≥2 组,比较两组的生长发育、生化和临床指标。

结果

193/402 次就诊时发现 17-羟孕酮(17-OHP)升高,53/193(27.5%)次就诊时发现促肾上腺皮质激素(ACTH)和总睾酮(tT)升高。GV SDS≥2 组中,17-OHP 的计算截断值为>4.3ng/ml,其灵敏度为 85.48%,特异性为 37.59%。在 GV SDS≥2 组中,校正终身高 SDS(cFH SDS)较低,身高差高于 GV SDS<2 组(p=0.005 和 p=0.008)。GV SDS 的线性回归分析显示,17-OHP 值和氢化可的松剂量(mg/m)受到影响(β=0.037,p=0.035 和 β=−0.147,p=0.001)。

结论

21-OHD 患儿的终身高(FH)与年度 GV 密切相关。然而,我们观察到随访中的生化参数存在不一致性,评估这些标志物存在困难。因此,21-OHD 患儿在随访中应同时使用年度 GV SDS 和生化发现。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验